This study investigates metastatic pancreatic adenocarcinoma. It evaluates the safety and efficacy of an investigational medication used alone or with chemotherapy compared to standard chemotherapy.
The study focuses on assessing whether the investigational medication improves progression-free survival and overall survival. It looks at how the medication performs as a first-line treatment.
- Who can participate: Adults 18 years and older with confirmed metastatic pancreatic adenocarcinoma can participate, with an ECOG performance status of 0 or 1 and adequate organ function.
- Study details: Participants will receive either the investigational RAS(ON) inhibitor alone, the investigational RAS(ON) inhibitor with chemotherapy, or standard chemotherapy.
How understandable was the trial content above?
Hard to understand
Easy to understand